MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-WB-10-0027190
Market Cap
₹137 Cr
NEPHROCARE-SM · NSE
Share Price
₹79.80
-3.86% today
Revenue
₹88.86 Cr
FY 2025-26
EBITDA
₹8.33 Cr
Margin 9.4%
Net Profit
₹2.81 Cr
FY 2025-26
P/E (TTM)
49.0x
P/B 2.4x
ROE
5.9%
ROCE 8.4%
Authorised capital
₹20 Cr
Registered with MCA
About Nephro Care India Limited
Data last updated:
Nephro Care India Limited is a public limited company based in Kolkata, West Bengal, India. It operates in the preventive healthcare segment of the healthcare sector. It was incorporated on 08 July 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN L85100WB2014PLC202429. Its GSTIN is 19AAECN7022L1Z7 (West Bengal). It is a listed company as per MCA records. Its shares are listed on NSE: NEPHROCARE.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹16.49 Cr. It is led by directors including Pratim Sengupta (Managing Director) and Pritam Sengupta.
Its last annual general meeting (AGM) was held on 28 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Flat No – 1Jc – 18 5th Floor Sec – III Saltlake, Kolkata, West Bengal, India – 700098.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹88.86 Cr. For the same year it recorded a net profit of ₹2.81 Cr (net margin 3.2%) and EBITDA of ₹8.33 Cr (EBITDA margin 9.4%). The net worth stands at ₹56.86 Cr. Total assets are valued at ₹57.31 Cr.
The company is associated with 1 brand: Nephrocare. The company has 5 deals on record (2 secondary share transfers, 1 rights issue, 1 ipo), with disclosed funding of ₹8.09 Cr; the latest was in July 2024.
Nephro Care India Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-WB-10-0027190). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nephrocareindia.com.
Company details
CIN L85100WB2014PLC202429
Registration Number 202429
Incorporation Date 08 July 2014
ROC Kolkata
Listing Status Listed (NSE: NEPHROCARE)
Company Status Active
Date of Last AGM 28 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-WB-10-0027190
CIN history
Nephro Care India has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85100WB2014PLC202429, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85100WB2014PLC202429 | Current |
| U85100WB2014PLC202429 | Previous |
| U85100WB2014PTC202429 | Previous |
Key People
Pratim Sengupta Managing Director Pritam Sengupta Director Sandeep Shridhar Ghate Director Recognitions & Rankings of Nephro Care India
Contact details
Nephro Care India Limited's registered office is in Saltlake, West Bengal. Its website is nephrocareindia.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressFlat No – 1Jc – 18 5th Floor Sec – III Saltlake, Kolkata, West Bengal, India – 700098
- IndustryHealthcare, Preventive Health Services
To see the full contact details of Nephro Care India Limited, buy the company report.
Comprehensive company report
Nephro Care India Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Nephro Care India operates one associated brand: Nephrocare. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Standalone nephrology hospital services for kidney care are provided. | nephrocareindia.com |
Business activity
The main business activity of Nephro Care India is hospital and medical care. In detail, this covers hospital activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q1 | Hospital activities |
To see the full business activity and turnover split of Nephro Care India Limited, buy the company report.
Financials of Nephro Care India Limited
FY 2025-26 filings availableNephro Care India Limited reported revenue of ₹88.86 Cr for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹88.86 Cr
EBITDA
₹8.33 Cr
Profit After Tax
₹2.81 Cr
Net Worth
₹56.86 Cr
Total Assets
₹57.31 Cr
Total Debt
Nil
Financial summary ₹ Cr
| Metrics | FY 2025-26 |
|---|---|
| Income statement | |
| Revenue | 88.86 |
| EBITDA | 8.33 |
| EBITDA margin | +9.4% |
| Profit before tax | 4.65 |
| Net profit | 2.81 |
| Net profit margin | +3.2% |
| EPS (₹) | 2.04 |
| Balance sheet | |
| Total assets | 57.31 |
| Net worth | 56.86 |
| Total debt | 0.00 |
| Cash & bank | 6.49 |
| Net working capital | 5.50 |
| Cash flow | |
| Cash from operations | 2.21 |
| Cash from investing | (0.43) |
| Cash from financing | 0.05 |
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 29.19 | 26.75 | 17.33 |
| Revenue growth (YoY) | +68.4% | - | - |
| Other income | 0.22 | 0.83 | 0.05 |
| EBITDA | 3.62 | 2.03 | 0.60 |
| EBITDA margin | +12.4% | +7.6% | +3.5% |
| Depreciation | 1.19 | 1.56 | 1.16 |
| Interest | 0.03 | (0.01) | 0.14 |
| Profit before tax | 2.62 | 1.31 | (0.65) |
| Tax | 1.00 | 0.30 | 0.00 |
| Net profit | 1.62 | 1.01 | (0.65) |
| EPS (₹) | 0.98 | 0.61 | (0.39) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 88.73 | 46.13 | 27.59 | 18.21 | 3.42 | 1.82 | 0.54 |
| Revenue growth | +92.4% | +67.2% | +51.5% | +432.5% | +87.9% | +237.0% | - |
| EBITDA | 8.32 | 5.88 | 6.37 | 3.43 | 0.13 | 0.15 | 0.00 |
| EBITDA margin | +9.4% | +12.8% | +23.1% | +18.8% | +3.8% | +8.2% | 0.0% |
| Profit before tax | 4.64 | 4.84 | 6.12 | 2.58 | 0.00 | 0.12 | (0.03) |
| Net profit | 3.37 | 2.88 | 4.30 | 2.38 | (0.40) | 0.09 | (0.03) |
| Net profit margin | +3.8% | +6.2% | +15.6% | +13.1% | -11.7% | +5.0% | -5.6% |
| EPS (₹) | 2.04 | 2.21 | 3.71 | 47.45 | (0.20) | 88.70 | (14.78) |
| Balance sheet | |||||||
| Total assets | 57.26 | 53.95 | 15.10 | 5.01 | 3.05 | 0.72 | 0.47 |
| Net worth | 56.86 | 53.49 | 15.02 | 2.53 | 0.50 | 0.02 | 0.08 |
| Total debt | 0.00 | 0.00 | 0.00 | 2.48 | 2.54 | 0.69 | 0.40 |
| Cash & bank | 6.39 | 4.66 | 1.29 | 2.32 | 0.61 | 0.48 | 0.04 |
| Net working capital | 5.40 | (1.78) | (1.47) | (0.31) | (0.49) | 0.11 | (0.21) |
| Cash flow | |||||||
| Cash from operations | 2.21 | 7.24 | 0.91 | 4.12 | 0.62 | 0.23 | - |
| Cash from investing | (0.48) | (39.83) | (7.54) | (2.33) | (2.81) | (0.06) | - |
| Cash from financing | 0.00 | 35.96 | 5.60 | (0.08) | 2.32 | 0.28 | - |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 29.19 | 26.75 | 22.66 | 21.99 | 17.33 | 7.48 | 6.65 |
| Revenue growth (YoY) | +68.4% | - | - | - | - | - | - |
| Other income | 0.22 | 0.83 | 0.08 | 0.57 | 0.05 | 0.23 | 0.10 |
| Total expenses | 25.57 | 24.72 | 20.75 | 18.20 | 16.73 | 6.15 | 5.25 |
| EBITDA | 3.62 | 2.03 | 1.91 | 3.79 | 0.60 | 1.33 | 1.40 |
| EBITDA margin | +12.4% | +7.6% | +8.4% | +17.2% | +3.5% | +17.8% | +21.1% |
| Depreciation | 1.19 | 1.56 | 1.40 | 0.95 | 1.16 | 0.01 | 0.51 |
| Interest | 0.03 | (0.01) | 0.03 | (0.01) | 0.14 | 0.00 | 0.03 |
| Profit before tax | 2.62 | 1.31 | 0.56 | 3.42 | (0.65) | 1.55 | 0.96 |
| Tax | 1.00 | 0.30 | 0.14 | 0.83 | 0.00 | 0.53 | 1.19 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 29.19 | 26.75 | 17.33 |
| Revenue growth (YoY) | +68.4% | - | - |
| Other income | 0.22 | 0.83 | 0.05 |
| EBITDA | 3.62 | 2.03 | 0.60 |
| EBITDA margin | +12.4% | +7.6% | +3.5% |
| Depreciation | 1.19 | 1.56 | 1.16 |
| Interest | 0.03 | (0.01) | 0.14 |
| Profit before tax | 2.62 | 1.31 | (0.65) |
| Tax | 1.00 | 0.30 | 0.00 |
| Net profit | 1.62 | 1.01 | (0.65) |
| EPS (₹) | 0.98 | 0.61 | (0.39) |
| Particulars | FY 2025-26 |
|---|---|
| Revenue | 88.86 |
| Other income | 1.55 |
| Total expenses | 80.53 |
| Employee cost | 14.83 |
| EBITDA | 8.33 |
| EBITDA margin | +9.4% |
| Depreciation | 5.07 |
| Interest | 0.16 |
| Profit before tax | 4.65 |
| Tax | 1.27 |
| Net profit | 2.81 |
| Net profit margin | +3.2% |
| EPS (₹) | 2.04 |
| Particulars | FY 2025-26 |
|---|---|
| Equity & liabilities | |
| Share capital | 16.49 |
| Reserves & surplus | 40.37 |
| Shareholders' funds (net worth) | 56.86 |
| Minority interest | 0.05 |
| Secured loans | 0.00 |
| Unsecured loans | 0.00 |
| Total debt | 0.00 |
| Total liabilities | 57.31 |
| Assets | |
| Gross block | 42.99 |
| Net block | 34.01 |
| Capital work in progress | 0.53 |
| Investments | 11.76 |
| Inventories | 2.29 |
| Sundry debtors | 6.04 |
| Cash & bank balances | 6.49 |
| Loans & advances | 5.95 |
| Total current assets | 20.77 |
| Total current liabilities | 15.27 |
| Net working capital | 5.50 |
| Total assets | 57.31 |
| Particulars | FY 2025-26 |
|---|---|
| Opening cash | 4.66 |
| Net cash from operating activities | 2.21 |
| Net cash from investing activities | (0.43) |
| Net cash from financing activities | 0.05 |
| Net change in cash | 1.83 |
| Closing cash | 6.49 |
| Particulars | FY 2025-26 |
|---|---|
| Growth | |
| PBT growth | +9997.0% |
| Profitability & leverage | |
| Net income margin | +3.8% |
| Return on capital employed | +8.4% |
| Return on net worth | +5.9% |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Interest cover | 4.91 |
| Efficiency & per share | |
| Fixed asset turnover | 2.07 |
| Inventory turnover | 38.80 |
| Debtors turnover | 14.71 |
| EPS (₹) | 2.04 |
| Dividend per share (₹) | 0.00 |
| Book value per share (₹) | 34.49 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 29.19 | 26.75 | 22.66 | 21.99 | 17.33 | 7.48 | 6.65 |
| Revenue growth (YoY) | +68.4% | - | - | - | - | - | - |
| Other income | 0.22 | 0.83 | 0.08 | 0.57 | 0.05 | 0.23 | 0.10 |
| Total expenses | 25.57 | 24.72 | 20.75 | 18.20 | 16.73 | 6.15 | 5.25 |
| EBITDA | 3.62 | 2.03 | 1.91 | 3.79 | 0.60 | 1.33 | 1.40 |
| EBITDA margin | +12.4% | +7.6% | +8.4% | +17.2% | +3.5% | +17.8% | +21.1% |
| Depreciation | 1.19 | 1.56 | 1.40 | 0.95 | 1.16 | 0.01 | 0.51 |
| Interest | 0.03 | (0.01) | 0.03 | (0.01) | 0.14 | 0.00 | 0.03 |
| Profit before tax | 2.62 | 1.31 | 0.56 | 3.42 | (0.65) | 1.55 | 0.96 |
| Tax | 1.00 | 0.30 | 0.14 | 0.83 | 0.00 | 0.53 | 1.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 88.73 | 46.13 | 27.59 | 18.21 | 3.42 | 1.82 | 0.54 |
| Revenue growth | +92.4% | +67.2% | +51.5% | +432.5% | +87.9% | +237.0% | - |
| Other income | 1.55 | 1.53 | 0.37 | 0.00 | 0.00 | 0.01 | 0.01 |
| Total expenses | 80.41 | 40.25 | 21.22 | 14.78 | 3.29 | 1.67 | 0.54 |
| Employee cost | 0.00 | 7.59 | 2.16 | 1.11 | 0.31 | 0.15 | 0.15 |
| EBITDA | 8.32 | 5.88 | 6.37 | 3.43 | 0.13 | 0.15 | 0.00 |
| EBITDA margin | +9.4% | +12.8% | +23.1% | +18.8% | +3.8% | +8.2% | 0.0% |
| Depreciation | 5.07 | 2.46 | 0.53 | 0.78 | 0.11 | 0.01 | 0.00 |
| Interest | 0.16 | 0.11 | 0.09 | 0.07 | 0.02 | 0.03 | 0.04 |
| Profit before tax | 4.64 | 4.84 | 6.12 | 2.58 | 0.00 | 0.12 | (0.03) |
| Tax | 1.27 | 1.19 | 1.72 | 0.20 | 0.01 | 0.03 | 0.00 |
| Net profit | 3.37 | 2.88 | 4.30 | 2.38 | (0.40) | 0.09 | (0.03) |
| Net profit margin | +3.8% | +6.2% | +15.6% | +13.1% | -11.7% | +5.0% | -5.6% |
| EPS (₹) | 2.04 | 2.21 | 3.71 | 47.45 | (0.20) | 88.70 | (14.78) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.49 | 16.49 | 11.90 | 0.50 | 0.50 | 0.01 | 0.01 |
| Reserves & surplus | 40.37 | 37.00 | 3.12 | 2.03 | 0.00 | 0.01 | 0.07 |
| Shareholders' funds (net worth) | 56.86 | 53.49 | 15.02 | 2.53 | 0.50 | 0.02 | 0.08 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.04 | 0.12 | 0.18 | 0.25 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 2.44 | 2.42 | 0.51 | 0.15 |
| Total debt | 0.00 | 0.00 | 0.00 | 2.48 | 2.54 | 0.69 | 0.40 |
| Total liabilities | 57.26 | 53.95 | 15.10 | 5.01 | 3.05 | 0.72 | 0.47 |
| Assets | |||||||
| Gross block | 42.99 | 35.39 | 6.18 | 3.92 | 1.52 | 0.07 | 0.45 |
| Net block | 34.01 | 31.49 | 4.74 | 3.01 | 1.39 | 0.06 | 0.45 |
| Capital work in progress | 0.53 | 0.61 | 0.86 | 0.00 | 1.90 | 0.45 | 0.00 |
| Investments | 11.81 | 18.58 | 6.51 | 2.00 | 0.00 | 0.00 | 0.24 |
| Inventories | 2.29 | 1.23 | 0.35 | 0.48 | 0.17 | 0.03 | 0.02 |
| Sundry debtors | 6.04 | 3.23 | 0.15 | 0.04 | 0.19 | 0.00 | 0.00 |
| Cash & bank balances | 6.39 | 4.66 | 1.29 | 2.32 | 0.61 | 0.48 | 0.04 |
| Loans & advances | 5.95 | 3.13 | 2.60 | 0.10 | 0.12 | 0.01 | 0.04 |
| Total current assets | 20.67 | 12.25 | 4.39 | 2.94 | 1.09 | 0.52 | 0.10 |
| Total current liabilities | 15.27 | 14.03 | 5.86 | 3.25 | 1.58 | 0.41 | 0.31 |
| Net working capital | 5.40 | (1.78) | (1.47) | (0.31) | (0.49) | 0.11 | (0.21) |
| Total assets | 57.26 | 53.95 | 15.10 | 5.01 | 3.05 | 0.72 | 0.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 4.66 | 1.29 | 2.32 | 0.61 | 0.48 | 0.04 | - |
| Net cash from operating activities | 2.21 | 7.24 | 0.91 | 4.12 | 0.62 | 0.23 | - |
| Net cash from investing activities | (0.48) | (39.83) | (7.54) | (2.33) | (2.81) | (0.06) | - |
| Net cash from financing activities | 0.00 | 35.96 | 5.60 | (0.08) | 2.32 | 0.28 | - |
| Net change in cash | 1.73 | 3.37 | (1.03) | 1.71 | 0.13 | 0.44 | - |
| Closing cash | 6.39 | 4.66 | 1.29 | 2.32 | 0.61 | 0.48 | - |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +92.4% | +67.2% | +51.5% | +432.5% | +87.9% | +237.0% | - |
| EBITDA growth | +41.5% | -7.7% | +85.7% | +2538.5% | -13.3% | - | - |
| PBT growth | -4.1% | -20.9% | +137.2% | +9997.0% | +9997.0% | +9998.0% | +9997.0% |
| Net income growth | +17.0% | -33.0% | +80.7% | +695.0% | -544.4% | +400.0% | - |
| Revenue CAGR (3Y) | +69.5% | +138.0% | +147.5% | +223.1% | - | - | - |
| EBITDA CAGR (3Y) | +34.4% | +256.3% | +248.9% | - | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +3.8% | +7.9% | +16.0% | +13.1% | -0.3% | +5.0% | -5.6% |
| Return on capital employed | - | +11.2% | +61.9% | +65.5% | +1.6% | +20.8% | +6.4% |
| Return on net worth | - | +8.4% | +50.3% | +156.4% | -153.9% | +450.0% | -12.5% |
| Debt / equity | - | 0.00 | 0.14 | 1.65 | 6.22 | 34.57 | 4.88 |
| Long-term debt / equity | - | 0.00 | 0.14 | 1.62 | 6.08 | 31.23 | 4.88 |
| Interest cover | 4.92 | 3.22 | 1.54 | 2.64 | 100.00 | 21.43 | - |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 2.22 | 5.46 | 6.69 | 4.30 | 26.00 | 1.20 |
| Inventory turnover | - | 58.39 | 66.48 | 56.03 | 34.20 | 60.67 | 27.00 |
| Debtors turnover | - | 27.30 | 290.42 | 158.35 | 36.00 | 0.00 | 0.00 |
| EPS (₹) | 2.04 | 2.21 | 3.71 | 47.45 | (0.20) | 88.70 | (14.78) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 32.44 | 12.62 | 50.57 | 9.90 | 15.00 | 82.01 |
To see the full year-wise statements and ratios of Nephro Care India Limited, buy the company report.
Board of directors of Nephro Care India Limited
Nephro Care India has 8 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pratim Sengupta Also directs: Dr Pratim's Academy LLP, Prakritaum Media & Advertising LLP, Abide Health Care Private Limited and 4 more | Managing Director | 08 Jul 2014 | 12 Years 3 Months | Current |
| Pritam Sengupta Also directs: Abide Health Care Private Limited | Director | 08 Jul 2014 | 12 Years 3 Months | Current |
| Sandeep Shridhar Ghate Also directs: Instafin Financial Advisors LLP, SG Dhanvarsha LLP, Securex Financial Services (India) Limited and 2 more | Director | 19 Jul 2024 | 2 Years 3 Months | Current |
| Debashish Ghoshal Also directs: Invictus Corporate Solutions LLP | Director | 19 Jul 2024 | 2 Years 3 Months | Current |
| Alo Sengupta | Director | 26 Dec 2023 | 2 Years 10 Months | Current |
| Saikat Biswas | Director | 26 Dec 2023 | 2 Years 10 Months | Current |
Showing 6 of 8 current directors. View all directors
Auditor
Nephro Care India Limited is audited by K K Chanani & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K K Chanani & Associates | FY 2024 | 322232E |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 61.70%, foreign institutional investors hold 1.00%, domestic institutional investors hold 1.20% and retail and other public shareholders hold 36.10%.
Sep 2026
QUARTER
61.70% Promoters
1.20% DII (Domestic Institutional)
1.00% FII (Foreign Institutional)
36.10% Retail & Others
Promoter holding - history
Now 61.70% · Sep 2026High 61.70% · Jun 2026Low 61.40% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 61.70% | 61.70% | 61.50% | 61.40% |
| Public | 38.30% | 38.30% | 38.50% | 38.60% |
Deals & funding
Nephro Care India Limited has 5 deals on record (2 secondary share transfers, 1 rights issue, 1 ipo), with disclosed funding of ₹8.09 Cr; the latest was in July 2024.
Total deals
5
Secondary share transfers
2
Rights issue
1
IPO
1
Funding round
1
Disclosed funding
₹8.09 Cr
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2024 | IPO | ₹41.26 Cr | Investors: IPO - Nephro Care India Limited, Ccv Emerging Opportunities Fund 1, Persistent Growth Fund- Varsu India Growth Story Scheme 1 |
| Feb 2024 | Secondary share transfer | Undisclosed | Buyer: Mindscope Advisors LLP Seller: Mindscope Services Private Limited |
| Jan 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Dec 2023 | Funding round | ₹8.09 Cr | Investors: Unizon Fintech Private Limited , 3 individuals |
| Nov 2021 | Rights issue | ₹49 Lakh | Investors: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Nephro Care India Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nephro Care India Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Nephro Care India has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 19AAECN7022L1Z7 | West Bengal | Active | 13 Dec 2019 |
To see the full GST registrations and return filing status of Nephro Care India Limited, buy the company report.
Recent activity
Nephro Care India Limited has 15 board changes on record since 2014: 13 appointments and 2 cessations. The latest: Somnath Chakraborty ceased to be CEO on 30 Sep 2024.
Filing
Nephro Care India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Kolkata Ii.
AGM
Nephro Care India Limited last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records.
Ceased
Somnath Chakraborty ceased to be CEO.
Appointed
Debashish Ghoshal was appointed as Director.
Appointed
Sandeep Shridhar Ghate was appointed as Director.
Appointed
Sougata Sengupta was appointed as Company Secretary.
Ceased
Rekha Shaw ceased to be Company Secretary.
Appointed
Alo Sengupta was appointed as Director.
Appointed
Alo Sengupta was appointed as Director.
Appointed
Saikat Biswas was appointed as Director.
Appointed
Sudip Barman was appointed as Director.
Appointed
Sutapa Sen was appointed as Director.
6 earlier events are in the company report.
News
Frequently asked questions
Nephro Care India is an active public limited company based in Kolkata, West Bengal, India. The company works in preventive health services, within the healthcare industry. It was incorporated on 08 July 2014 (12+ years old) and is registered under CIN L85100WB2014PLC202429. Listed on NSE: NEPHROCARE.
Nephro Care India reported revenue of ₹88.86 Cr for FY 2025-26 based on consolidated financials.
Nephro Care India has 8 current directors:
- Pratim Sengupta - Managing Director
- Pritam Sengupta - Director
- Sandeep Shridhar Ghate - Director
- Debashish Ghoshal - Director
- Alo Sengupta - Director
- Saikat Biswas - Director
- Sudip Barman - Director
- Sutapa Sen - Director
The latest financial statements of Nephro Care India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Nephro Care India is 19AAECN7022L1Z7, registered in West Bengal.
The CIN (Corporate Identification Number) of Nephro Care India is L85100WB2014PLC202429. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Nephro Care India is a listed company as per MCA records. Its shares are listed on NSE (symbol: NEPHROCARE).
Nephro Care India was incorporated on 08 July 2014, making it 12+ years old. It is registered with the Registrar of Companies, Kolkata.
Nephro Care India has 5 deals on record (2 secondary share transfers, 1 rights issue, 1 ipo), with disclosed funding of ₹8.09 Cr; the latest was in July 2024.
Somnath Chakraborty ceased to be CEO on 30 Sep 2024. Debashish Ghoshal was appointed as Director on 19 Jul 2024. Sandeep Shridhar Ghate was appointed as Director on 19 Jul 2024. Nephro Care India has 15 board changes on record in total.